3月28日周五，信达生物股价盘中大涨5.13%，引发市场关注。该公司近期公布的2024年业绩报告成为推动股价上涨的主要因素。
根据财报，信达生物2024年总收入达94.22亿元，同比增长51.8%。虽然公司仍录得9463.1万元亏损，但亏损幅度同比大幅收窄90.8%。更值得注意的是，在非国际财务报告准则（Non-IFRS）下，公司首次实现了自IPO以来的净利润和EBITDA转正，标志着其经营状况显著改善。
除了亮眼的业绩表现外，信达生物的未来发展前景也令投资者充满信心。公司预计2025年将推出两款潜在重磅产品："玛仕度肽"和"匹康奇拜单抗"。其中，全球首个GCG/GLP-1双重激动剂"玛仕度肽"的减重适应症预计将于2025年上半年获批上市。这些新产品的推出有望为公司带来新的增长动力，进一步提升其在创新药领域的竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.